<unk> , sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. The U.S. Food and Drug Administration (FDA) awarded orphan drug designation for acute myeloid leukemia and for cholangiocarcinoma.<unk>  is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to differentiation of malignant cells. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Ivosidenib
Enasidenib
Dabrafenib
Selpercatinib
Brigatinib
Tucatinib
Fostamatinib
Lorlatinib